Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Despite recent advances in therapeutic options, hepatitis C virus (HCV) remains a severe global disease burden, and a vaccine can substantially reduce its incidence. Due to its extremely high sequence variability, HCV can readily escape the immune response; thus, an effective vaccine must target conserved, functionally important epitopes. Using the structure of a broadly neutralizing antibody in complex with a conserved linear epitope from the HCV E2 envelope glycoprotein (residues 412 to 423; epitope I), we performed structure-based design of immunogens to induce antibody responses to this epitope. This resulted in epitope-based immunogens based on a cyclic defensin protein, as well as a bivalent immunogen with two copies of the epitope on the E2 surface. We solved the X-ray structure of a cyclic immunogen in complex with the HCV1 antibody and confirmed preservation of the epitope conformation and the HCV1 interface. Mice vaccinated with our designed immunogens produced robust antibody responses to epitope I, and their serum could neutralize HCV. Notably, the cyclic designs induced greater epitope-specific responses and neutralization than the native peptide epitope. Beyond successfully designing several novel HCV immunogens, this study demonstrates the principle that neutralizing anti-HCV antibodies can be induced by epitope-based, engineered vaccines and provides the basis for further efforts in structure-based design of HCV vaccines. IMPORTANCE Hepatitis C virus is a leading cause of liver disease and liver cancer, with approximately 3% of the world's population infected. To combat this virus, an effective vaccine would have distinct advantages over current therapeutic options, yet experimental vaccines have not been successful to date, due in part to the virus's high sequence variability leading to immune escape. In this study, we rationally designed several vaccine immunogens based on the structure of a conserved epitope that is the target of broadly neutralizing antibodies. In vivo results in mice indicated that these antigens elicited epitope-specific neutralizing antibodies, with various degrees of potency and breadth. These promising results suggest that a rational design approach can be used to generate an effective vaccine for this virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770 · cited 5×
“have been explored for other viruses, such as HIV (15, 16), influenza virus (17, 18), and”
BackgroundInfluentialProof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · cited 2×
“Such structure-based vaccine design approaches have been explored for other viruses, such as HIV (15, 16), influenza virus (17, 18), and respiratory syncytial virus (RSV) (19, 20), with promising results, though in some cases neutralizing antibodies were not successfully induced in vivo, possibly due to the epitope’s…”
BackgroundElicitation of structure-specific antibodies by epitope scaffolds
Ofek, G., Guenaga, F. J., Schief, W. R., Skinner, J., Baker, D., Wyatt, R., & Kwong, P. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004728107 · Cited by 278 · cited 6×
“have been explored for other viruses, such as HIV (15, 16), influenza virus (17, 18), and”
BackgroundInfluential
Cited by
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
“56, 57 These included two cyclic peptides, C1 and C2, that used the β-hairpin structure of θ-defensin as a scaffold to present the HCV epitope ( Figure 5 ).”
BackgroundCurrent Challenges in Vaccinology
Kennedy, R. B., Ovsyannikova, I. G., Palese, P., & Poland, G. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01181 · Cited by 113
“Antibody-antigen complexes can also be determined, providing insights into critical antibody functionality such as neutralization or have identified critical conserved regions that can be targeted for more effective immune responses (87).”
BackgroundPeptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Metadata
- Authors
- Pierce, B. G., Boucher, E. N., Piepenbrink, K. H., Ejemel, M., Rapp, C. A., Thomas, W. D., Sundberg, E. J., Weng, Z., & Wang, Y.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2017-10-15
- Volume
- 91
- Issue
- 20
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2744934168
- Cited by
- 63
- References
- 4
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. https://app.cochat.ai/papers/10.1128/jvi.01032-17
- The paper
- Pierce, B. G., Boucher, E. N., Piepenbrink, K. H., Ejemel, M., Rapp, C. A., Thomas, W. D., Sundberg, E. J., Weng, Z., & Wang, Y. (2017). Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Journal of Virology. https://doi.org/10.1128/jvi.01032-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.